Brief: Dermapharm FY Adjusted EBITDA Up 13% To EUR 201 Million

Dermapharm Holding SE

30/03/2021 06:35

March 30 (Reuters) - Dermapharm Holding SE  DMPG.DE :
    * DGAP-NEWS: DERMAPHARM POSTS GROWTH DESPITE COVID-19
PANDEMIC -
CONSOLIDATED REVENUE AND EBITDA CONTINUE TO RISE
    * FY REVENUE ROSE 13 PERCENT TO 794 MILLION EUR
    * FY CONSOLIDATED REVENUE UP YEAR ON YEAR BY APPROXIMATELY
13 % TO
EUR 794 MILLION
    * FY ADJUSTED EBITDA INCREASES BY APPROXIMATELY 13 % TO EUR
201
MILLION
    * COOPERATION WITH BIONTECH SE ON VACCINE PRODUCTION
EXPANDED
    * CURRENTLY EXPANDING ALLERGOPHARMA'S VACCINE PRODUCTION
CAPACITIES IN REINBEK, NEAR HAMBURG. PRODUCTION IS SCHEDULED TO
COMMENCE IN MAY 2021.

Source text for Eikon:  ID:nEQc89c7Za 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))